This is an old revision of this page, as edited by 72.199.145.236 (talk) at 06:53, 2 February 2011 (→External links). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 06:53, 2 February 2011 by 72.199.145.236 (talk) (→External links)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compoundFile:HT-0712.png | |
Clinical data | |
---|---|
Other names | HT-0712, IPL 455,903 |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C25H31NO3 |
Molar mass | 393.53 g/mol g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(verify) |
HT-0712 is an experimental cognitive enhancing drug (nootropic) which is currently undergoing clinical trials. It is currently being licensed by Helicon Therapeutics in San Diego, California. It was originally discovered and tested as part of a preclinical anti-inflammatory program by Inflazyme Pharmaceuticals.
Mechanism of action
HT-0712 appears to act as a PDE4 inhibitor, thereby increasing cAMP levels. When cAMP levels are increased in neurons, this may trigger activation of cAMP response element-binding proteins (CREB). CREBs are transcription factors involved in the formation of long-term memory.
The side effects of the drug are not yet fully known.
Medical use
Middle-aged people, seniors, and possibly those suffering from dementia, who have a hard time remembering everyday events, can possibly benefit from this drug.
Performance enhancing use
Many students may be inclined to use nootropics for school and college life for exams and finals. This could also be an effective alternative or adjunctive to the use of caffeine as a study aid.
References
United States Patent 20040224316
External links
- Helicon Therapeutics
- PDF file regarding Helicon's commencement of Phase I trials
- News article on HT-0712
This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |